Structure Therapeutics (GPCR) Free Cash Flow (2022 - 2026)

Structure Therapeutics' Free Cash Flow history runs 5 years deep, the most recent figure standing at $14.1 million for Q1 2026.

• On a quarterly basis, Free Cash Flow rose 126.4% year-over-year to $14.1 million in Q1 2026; TTM through Mar 2026 was -$158.5 million, a 12.57% decrease from a year earlier, with the FY2025 full-year figure at -$225.8 million, down 85.55% from the prior year.
• Free Cash Flow improved to $14.1 million in Q1 2026 per GPCR's latest filing, from -$66.5 million in the prior quarter.
• Across five years, Free Cash Flow topped out at $14.1 million in Q1 2026 and bottomed at -$66.5 million in Q4 2025.
• The 5-year median for Free Cash Flow is -$20.9 million (2023), against an average of -$27.0 million.
• Across the five-year window, Free Cash Flow sank 154.86% in 2025 and soared 126.4% in 2026, its largest moves.
• Year by year, Free Cash Flow stood at -$12.0 million in 2022, then tumbled by 78.85% to -$21.5 million in 2023, then plunged by 87.53% to -$40.3 million in 2024, then sank by 65.29% to -$66.5 million in 2025, then surged by 121.12% to $14.1 million in 2026.
• Per Business Quant, the three latest GPCR Free Cash Flow figures stand at $14.1 million (Q1 2026), -$66.5 million (Q4 2025), and -$51.9 million (Q3 2025).